Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Inclusion Criteria:

1. Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6months or more. Stable psoriasis is defined as no morphology changes or significantflares of disease activity in the opinion of the Investigator

2. Deemed by the Investigator to be a candidate for phototherapy or systemic therapy

3. Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's GlobalAssessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp SeverityIndex (PSSI) ≥ 12 at the Screening visit and Day 1

4. ≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1

5. Evidence of plaque psoriasis in a non-scalp area

6. Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis

Exclusion Criteria:

• Target Disease Exceptions:

1. Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic ordrug-induced psoriasis) at Screening or Day 1 Other protocol-definedinclusion/exclusion criteria apply